P2X receptors as drug targets

Molecular Pharmacology

Volumn 83, Issue 4, 2013, Pages 759-769

  North, R Alan ^a   Jarvis, Michael F ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ABBVIE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; PURINERGIC P2X RECEPTOR; PURINERGIC P2X1 RECEPTOR; PURINERGIC P2X3 RECEPTOR; PURINERGIC P2X7 RECEPTOR; PYRIDOXAL PHOSPHATE 6 AZOPHENYL 2',4' DISULFONIC ACID; QUINIDINE; SURAMIN;

CHRONIC PAIN; DRUG TARGETING; MOLECULAR MODEL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; X RAY CRYSTALLOGRAPHY;

ANIMALS; CRYSTALLOGRAPHY, X-RAY; DRUG DELIVERY SYSTEMS; HUMANS; PURINERGIC AGONISTS; PURINERGIC ANTAGONISTS; RECEPTORS, PURINERGIC P2X;

EID: 84875426837     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.083758     Document Type: Review

References (115)

1. Ahlquist RP (1948) A study of the adrenotropic receptors. Am J Physiol 153: 586-600.
2. Albers-Schönberg G, Arson BH, Chabala JC, Douglas AW, Eskola P, Fisher MH, Lusi A, Mrozik H, Smith JL, and Tolman RL (1981) Avermectins: structure determination. J Am Chem Soc 103:4216-4221.
3. Alexander SPH, Mathie A, and Peters JA(2011) Guide to receptors and channels (GRAC), 5th edition. Br J Pharmacol 164:S1-S324.
4. Allsopp RC and Evans RJ (2011) The intracellular amino terminus plays a dominant role in desensitization of ATP-gated P2X receptor ion channels. J Biol Chem 286: 44691-44701.
5. Arunlakshana O and Schild HO (1959) Some quantitative uses of drug antagonists. Br Pharmacol Chemother 14:48-58.
6. Baconguis I and Gouaux E (2012) Structural plasticity and dynamic selectivity of acid-sensing ion channel-spider toxin complexes. Nature 489:400-405.
7. Ballini E, Virginio C, Medhurst SJ, Summerfield SG, Aldegheri L, Buson A, Carignani C, Chen YH, Giacometti A, and Lago I et al. (2011) Characterization of three diaminopyrimidines as potent and selective antagonists of P2X3 and P2X2/3 receptors with in vivo efficacy in a pain model. Br J Pharmacol 163:1315-1325.
8. Baqi Y, Hausmann R, Rosefort C, Rettinger J, Schmalzing G, and Müller CE (2011) Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor. J Med Chem 54:817-830.
9. Basbaum AI, Bautista DM, Scherrer G, and Julius D (2009) Cellular and molecular mechanisms of pain. Cell 139:267-284.
10. Basoglu OK, Pelleg A, Essilfie-Quaye S, Brindicci C, Barnes PJ, and Kharitonov SA (2005) Effects of aerosolized adenosine 59-triphosphate vs adenosine 59-monophosphate on dyspnea and airway caliber in healthy nonsmokers and patients with asthma. Chest 128:1905-1909.
11. Bland-Ward PA and Humphrey PPA (1997) Acute nociception mediated by hindpaw P2X receptor activation in the rat. Br J Pharmacol 122:365-371.
12. Bleehen T and Keele CA (1977) Observations on the algogenic actions of adenosine compounds on the human blister base preparation. Pain 3:367-377.
13. Bowie D (2008) Ionotropic glutamate receptors & CNS disorders. CNS Neurol Disord Drug Targets 7:129-143.
14. Brake AJ, Wagenbach MJ, and Julius D (1994) New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor. Nature 371:519-523.
15. Brederson JD and Jarvis MF (2008) Homomeric and heteromeric P2X3 receptors in peripheral sensory neurons. Curr Opin Investig Drugs 9:716-725.
16. Broom DC, Matson DJ, Bradshaw E, Buck ME, Meade R, Coombs S, Matchett M, Ford KK, Yu W, and Yuan J et al. (2008) Characterization of N-(adamantan-1- ylmethyl)-5-[(3R-amino-pyrrolidin-1-yl)methyl]-2-chloro-benzamide, a P2X7 antagonist in animal models of pain and inflammation. J Pharmacol Exp Ther 327: 620-633.
17. Bültmann R, Trendelenburg M, and Starke K (1994) Blockade of P2X-purinoceptors by trypan blue in rat vas deferens. Br J Pharmacol 113:349-354.
18. Burnstock G (1972) Purinergic nerves. Pharmacol Rev 24:509-581.
19. Burnstock G (1978) A basis for distinguishing two types of purnergic receptor, in Cell membrane receptors for drugs and hormones: A multidisciplinary approach (Straub RW and Boils L eds) pp 107-118, Raven Press, New York.
20. Burnstock G (2007) Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev 87:659-797.
21. Burnstock G and Kennedy C (1985) Is there a basis for distinguishing two types of P2-purinoceptor? Gen Pharmacol 16:433-440.
22. Cantin L, Bayrakdarian M, Buon C, Hu Y, Kennedy V, Laplante M, Leung C, Luo X, Popovic N, Rene O et al.(2010) Pyrrolopyrimidine-based P2X3 antagonists for the treatment of pain. ACS National Meeting, Boston, MA; August 24-26, MEDI-474.
23. Cantin LD, Bayrakdarian M, Buon C, Grazzini E, Hu YJ, Labrecque J, Leung C, Luo X, Martino G, and Paré M et al. (2012) Discovery of P2X3 selective antagonists for the treatment of chronic pain. Bioorg Med Chem Lett 22:2565-2571.
24. Cao L, Young MT, Broomhead HE, Fountain SJ, and North RA (2007) Thr339-toserine substitution in rat P2X2 receptor second transmembrane domain causes constitutive opening and indicates a gating role for Lys308. J Neurosci 27: 12916-12923.
25. Carter DS, Alam M, Cai H, Dillon MP, Ford APDW, Gever JR, Jahangir A, Lin C, Moore AG, and Wagner PJ et al. (2009) Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. Bioorg Med Chem Lett 19:1628-1631.
26. Chaumont S, Compan V, Toulme E, Richler E, Housley GD, Rassendren F, and Khakh BS (2008) Regulation of P2X2 receptors by the neuronal calcium sensor VILIP1. Sci Signal 1:ra8.
27. Chessell IP, Hatcher JP, Bountra C,Michel AD, Hughes JP, Green P, Egerton J,Murfin M, Richardson J, and Peck WL et al. (2005) Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain 114:386-396.
28. Cinkilic O, King BF, van der Giet M, Schlüter H, Zidek W, and Burnstock G (2001) Selective agonism of group I P2X receptors by dinucleotides dependent on a single adenine moiety. J Pharmacol Exp Ther 299:131-136.
29. Coddou C, Stojilkovic SS, and Huidobro-Toro JP (2011) Allosteric modulation of ATPgated P2X receptor channels. Rev Neurosci 22:335-354.
30. Cully DF, Vassilatis DK, Liu KK, Paress PS, Van der Ploeg LH, Schaeffer JM, and Arena JP (1994) Cloning of an avermectin-sensitive glutamate-gated chloride channel from Caenorhabditis elegans. Nature 371:707-711.
31. Damer S, Niebel B, Czeche S, Nickel P, Ardanuy U, Schmalzing G, Rettinger J, Mutschler E, and Lambrecht G (1998) NF279: a novel potent and selective antagonist of P2X receptor-mediated responses. Eur J Pharmacol 350:R5-R6.
32. Di Virgilio F (2006) Purinergic signalling between axons and microglia, in Purinergic signalling in neuron-glia interactions. No. 276 (Chadwick DJ and Goode J eds) pp 253-262, Wiley, Chichester.
33. Donnelly-Roberts DL and Jarvis MF (2007) Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states. Br J Pharmacol 151:571-579.
34. Donnelly-Roberts D, McGaraughty S, Shieh C-C, Honore P, and Jarvis MF (2008) Painful purinergic receptors. J Pharmacol Exp Ther 324:409-415.
35. Donnelly-Roberts DL, Namovic MT, Han P, and Jarvis MF (2009) Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors. Br J Pharmacol 157:1203-1214.
36. Du J, Dong H, and Zhou HX (2012) Gating mechanism of a P2X4 receptor developed from normal mode analysis and molecular dynamics simulations. Proc Natl Acad Sci USA 109:4140-4145.
37. Eickhorst AN, Berson A, Cockayne D, Lester HA, and Khakh BS (2002) Control of P2X(2) channel permeability by the cytosolic domain. J Gen Physiol 120:119-131.
38. Ferrari D, Pizzirani C, Adinolfi E, Lemoli RM, Curti A, Idzko M, Panther E, and DiVirgilio F (2006) The P2X7 receptor: a key player in IL-1 processing and release. J Immunol 176:3877-3883.
39. Ford AP (2012) In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization. Purinergic Signal 8 (Suppl 1):3-26.
40. Gargett CE and Wiley JS (1997) The isoquinoline derivative KN-62 a potent antagonist of the P2Z-receptor of human lymphocytes. Br J Pharmacol 120:1483-1490.
41. Gever JR, Cockayne DA, Dillon MP, Burnstock G, and Ford APDW (2006) Pharmacology of P2X channels. Pflugers Arch 452:513-537.
42. Gever JR, Soto R, Henningsen RA, Martin RS, Hackos DH, Panicker S, Rubas W, Oglesby IB, Dillon MP, and Milla ME et al. (2010) AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist. Br J Pharmacol 160: 1387-1398.
43. Gordon JL (1986) Extracellular ATP: effects, sources and fate. Biochem J 233: 309-319.
44. Guile SD, Alcaraz L, Birkinshaw TN, Bowers KC, Ebden MR, Furber M, and Stocks MJ (2009) Antagonists of the P2X(7) receptor. From lead identification to drug development. J Med Chem 52:3123-3141.
45. Gum RJ, Wakefield B, and Jarvis MF (2012) P2X receptor antagonists for pain management: examination of binding and physicochemical properties. Purinergic Signal 8 (Suppl 1):41-56.
46. Hattori M and Gouaux E (2012) Molecular mechanism of ATP binding and ion channel activation in P2X receptors. Nature 485:207-212.
47. Hamilton SG and McMahon SB (2000) ATP as a peripheral mediator of pain. J Auton Nerv Syst 81:187-194.
48. Hausmann R, Günther J, Kless A, Kuhlmann D, Kassack MU, Bahrenberg G, Markwardt F, and Schmalzing G (2013) Salt bridge switching from Arg290/Glu167 to Arg290/ATP promotes the closed-to-open transition of the P2X2 receptors. Mol Pharmacol 83:73-84.
49. Hernandez-Olmos V, Abdelrahman A, El-Tayeb A, Freudendahl D, Weinhausen S, and Müller CE (2012) N-substituted phenoxazine and acridone derivatives: structure-activity relationships of potent P2X4 receptor antagonists. J Med Chem 55:9576-9588.
50. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, and Julius D et al. (2001) Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409:202-207.
51. Honore P, Donnelly-Roberts D, Namovic MT, Hsieh G, Zhu CZ, Mikusa JP, Hernandez G, Zhong C, Gauvin DM, and Chandran P et al. (2006) A-740003 [N-(1-[(cyanoimino)(5-quinolinylamino) methyl]amino-2,2-dimethylpropyl)-2-(3,4- dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat. J Pharmacol Exp Ther 319:1376-1385.
52. Honore P, Donnelly-Roberts D, Namovic M, Zhong C, Wade C, Chandran P, Zhu C, Carroll W, Perez-Medrano A, and Iwakura Y et al. (2009) The antihyperalgesic activity of a selective P2X7 receptor antagonist, A-839977, is lost in IL-1alphabeta knockout mice. Behav Brain Res 204:77-81.
53. Humphreys BD, Virginio C, Surprenant A, Rice J, and Dubyak GR (1998) Isoquinolines as antagonists of the P2X7 nucleotide receptor: high selectivity for the human versus rat receptor homologues. Mol Pharmacol 54:22-32.
54. Hurst R, Rollema H, and Bertrand D(2012) Nicotinic acetylcholine receptors: from basic science to therapeutics. Pharmacol Ther DOI: 10.1016/j.pharmthera.2012.08.012.
55. Iglesias R, Locovei S, Roque A, Alberto AP, Dahl G, Spray DC, and Scemes E (2008) P2X7 receptor-Pannexin1 complex: pharmacology and signaling. Am J Physiol Cell Physiol 295:C752-C760.
56. Inoue K (2006) The function of microglia through purinergic receptors: neuropathic pain and cytokine release. Pharmacol Ther 109:210-226.
57. Inoue K, Tsuda M, and Tozaki-Saitoh H (2007) Modification of neuropathic pain sensation through microglial ATP receptors. Purinergic Signal 3:311-316.
58. Jacobson KA and Boeynaems J-M (2010) P2Y nucleotide receptors: promise of therapeutic applications. Drug Discov Today 15:570-578.
59. Jacobson KA, Costanzi S, Joshi BV, Besada P, Shin DH, Ko H, Ivanov AA, and Mamedova L (2006) Agonists and antagonists for P2 receptors. Novartis Found Symp 276:58-68, discussion 68-72, 107-112, 275-281.
60. Jacobson KA, Jarvis MF, and Williams M (2002) Purine and pyrimidine (P2) receptors as drug targets. J Med Chem 45:4057-4093.
61. Jarvis MF (2010) The neural-glial purinergic receptor ensemble in chronic pain states. Trends Neurosci 33:48-57.
62. Jarvis MF, Burgard EC, McGaraughty S, Honore P, Lynch K, Brennan TJ, Subieta A, Van Biesen T, Cartmell J, and Bianchi B et al. (2002) A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat. Proc Natl Acad Sci USA 99: 17179-17184.
63. Jarvis MF and Khakh BS (2009) ATP-gated P2X cation-channels. Neuropharmacology 56:208-215.
64. Jarvis MF, Wismer CT, Schweitzer E, Yu H, van Biesen T, Lynch KJ, Burgard EC, Kowaluk EA, and Kowaluk EA (2001) Modulation of BzATP and formalin induced nociception: attenuation by the P2X receptor antagonist, TNP-ATP and enhancement by the P2X(3) allosteric modulator, cibacron blue. Br J Pharmacol 132:259-269.
65. Jelínkova I, Vávra V, Jindrichova M, Obsil T, Zemkova HW, Zemkova H, and Stojilkovic SS (2008) Identification of P2X(4) receptor transmembrane residues contributing to channel gating and interaction with ivermectin. Pflugers Arch 456: 939-950.
66. Jiang L-H, Mackenzie AB, North RA, and Surprenant A (2000) Brilliant blue G selectively blocks ATP-gated rat P2X(7) receptors. Mol Pharmacol 58:82-88.
67. Jiang R, Taly A, Lemoine D, Martz A, Cunrath O, and Grutter T (2012) Tightening of the ATP-binding sites induces the opening of P2X receptor channels. EMBO J 31: 2134-2143.
68. Jo S and Bean BP (2011) Inhibition of neuronal voltage-gated sodium channels by brilliant blue G. Mol Pharmacol 80:247-257.
69. Kaczmarek-Hájek K, Lörinczi E, Hausmann R, and Nicke A (2012) Molecular and functional properties of P2X receptors-recent progress and persisting challenges. Purinergic Signal 8:375-417.
70. Kamei J and Takahashi Y (2006) Involvement of ionotropic purinergic receptors in the histamine-induced enhancement of the cough reflex sensitivity in guinea pigs. Eur J Pharmacol 547:160-164.
71. Krause RM, Buisson B, Bertrand S, Corringer PJ, Galzi JL, Changeux JP, and Bertrand D (1998) Ivermectin: a positive allosteric effector of the α7 neuronal nicotinic acetylcholine receptor. Mol Pharmacol 53:283-294.
72. Kawate T, Michel JC, Birdsong WT, and Gouaux E (2009) Crystal structure of the ATP-gated P2X(4) ion channel in the closed state. Nature 460:592-598.
73. Keystone EC, Wang MM, Layton M, Hollis S, and McInnes IB; D1520C00001 Study Team (2012) Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis 71:1630-1635.
74. Khakh BS, Bao XR, Labarca C, and Lester HA (1999a) Neuronal P2X transmitter-gated cation channels change their ion selectivity in seconds. Nat Neurosci 2:322-330.
75. Khakh BS and North RA (2012) Neuromodulation by extracellular ATP and P2X receptors in the CNS. Neuron 76:51-69.
76. Khakh BS, Proctor WR, Dunwiddie TV, Labarca C, and Lester HA (1999b) Allosteric control of gating and kinetics at P2X(4) receptor channels. J Neurosci 19: 7289-7299.
77. Kim M, Jiang LH, Wilson HL, North RA, and Surprenant A (2001) Proteomic and functional evidence for a P2X7 receptor signalling complex. EMBO J 20:6347-6358.
78. Kleene SJ (1994) Inhibition of olfactory cyclic nucleotide-activated current by calmodulin antagonists. Br J Pharmacol 111:469-472.
79. Klöckner U and Isenberg G (1987) Calmodulin antagonists depress calcium and potassium currents in ventricular and vascular myocytes. Am J Physiol 253: H1601-H1611.
80. Krüsek J and Zemková H (1994) Effect of ivermectin on gamma-aminobutyric acidinduced chloride currents in mouse hippocampal embryonic neurones. Eur J Pharmacol 259:121-128.
81. Labasi JM, Petrushova N, Donovan C, McCurdy S, Lira P, Payette MM, Brissette W, Wicks JR, Audoly L, and Gabel CA (2002) Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. J Immunol 168:6436-6445.
82. Lewis CJ, Surprenant A, and Evans RJ (1998) 29,39-O-(2,4,6- trinitrophenyl) adenosine 59-triphosphate (TNP-ATP)-a nanomolar affinity antagonist at rat mesenteric artery P2X receptor ion channels. Br J Pharmacol 124:1463-1466.
83. Lörinczi É, Bhargava Y, Marino SF, Taly A, Kaczmarek-Hájek K, Barrantes-Freer A, Dutertre S, Grutter T, Rettinger J, and Nicke A (2012) Involvement of the cysteinerich head domain in activation and desensitization of the P2X1 receptor. Proc Natl Acad Sci USA 109:11396-11401.
84. Lu SH, Groat WC, Lin AT, Chen KK, and Chang LS (2007) Evaluation of purinergic mechanism for the treatment of voiding dysfunction: a study in conscious spinal cord-injured rats. J Chin Med Assoc 70:439-444.
85. MacKenzie A, Wilson HL, Kiss-Toth E, Dower SK, North RA, and Surprenant A (2001) Rapid secretion of interleukin-1beta by microvesicle shedding. Immunity 15: 825-835.
86. Masin M, Kerschensteiner D, Dümke K, Rubio ME, and Soto F (2006) Fe65 interacts with P2X2 subunits at excitatory synapses and modulates receptor function. J Biol Chem 281:4100-4108.
87. McGaraughty S, Chu KL, Namovic MT, Donnelly-Roberts DL, Harris RR, Zhang X-F, Shieh C-C, Wismer CT, Zhu CZ, and Gauvin DM et al. (2007) P2X7-related modulation of pathological nociception in rats. Neuroscience 146:1817-1828.
88. Miller CM, Boulter NR, Fuller SJ, Zakrzewski AM, Lees MP, Saunders BM, Wiley JS, and Smith NC (2011) The role of the P2X7 receptor in infectious diseases. PLoS Pathog 7:e1002212.
89. Müller CE (2010) Emerging structures and ligands for P2X3 and P2X4 receptorstowards novel treatments of neuropathic pain. Purinergic Signal 6:145-148.
90. Nagaya N, Tittle RK, Saar N, Dellal SS, and Hume RI (2005) An intersubunit zinc binding site in rat P2X2 receptors. J Biol Chem 280:25982-25993.
91. North RA (2002) Molecular physiology of P2X receptors. Physiol Rev 82:1013-1067.
92. Perl ER (2007) Ideas about pain, a historical view. Nat Rev Neurosci 8:71-80.
93. Perregaux DG and Gabel CA (1994) Interleukin-1 b maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J Biol Chem 269:15195-15203.
94. Priel A and Silberberg SD (2004) Mechanism of ivermectin facilitation of human P2X4 receptor channels. J Gen Physiol 123:281-293.
95. Rettinger J, Braun K, Hochmann H, Kassack MU, Ullmann H, Nickel P, Schmalzing G, and Lambrecht G (2005) Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analogue NF449 as a highly potent P2X1 receptor antagonist. Neuropharmacology 48:461-468.
96. Samways DS and Egan TM (2007) Acidic amino acids impart enhanced Ca2+ permeability and flux in two members of the ATP-gated P2X receptor family. J Gen Physiol 129:245-256.
97. Samways DS, Khakh BS, Dutertre S, and Egan TM (2011) Preferential use of unobstructed lateral portals as the access route to the pore of human ATP-gated ion channels (P2X receptors). Proc Natl Acad Sci USA 108:13800-13805.
98. Samways DS, Khakh BS, and Egan TM (2012) Allosteric modulation of Ca2+ flux in ligand-gated cation channel (P2X4) by actions on lateral portals. J Biol Chem 287: 7594-7602.
99. Silberberg SD, Li M, and Swartz KJ (2007) Ivermectin Interaction with transmembrane helices reveals widespread rearrangements during opening of P2X receptor channels. Neuron 54:263-274.
100. Soltoff SP, McMillian MK, and Talamo BR (1989) Coomassie Brilliant Blue G is a more potent antagonist of P2 purinergic responses than Reactive Blue 2 (Cibacron Blue 3GA) in rat parotid acinar cells. Biochem Biophys Res Commun 165: 1279-1285.
101. Sorge RE, Trang T, Dorfman R, Smith SB, Beggs S, Ritchie J, Austin JS, Zaykin DV, Vander Meulen H, and Costigan M et al. (2012) Genetically determined P2X7 receptor pore formation regulates variability in chronic pain sensitivity. Nat Med 18:595-599.
102. Surprenant A, Rassendren F, Kawashima E, North RA, and Buell G (1996) The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science 272:735-738.
103. Tittle RK, Power JM, and Hume RI (2007) A histidine scan to probe the flexibility of the rat P2X2 receptor zinc-binding site. J Biol Chem 282:19526-19533.
104. Tozaki-Saitoh H, Tsuda M, and Inoue K (2011) Role of purinergic receptors in CNS function and neuroprotection. Adv Pharmacol 61:495-528.
105. Trang T and Salter MW (2012) P2X4 purinoceptor signaling in chronic pain. Purinergic Signal 8:621-628.
106. Undem BJ and Nassenstein C (2009) Airway nerves and dyspnea associated with inflammatory airway disease. Respir Physiol Neurobiol 167:36-44.
107. Valera S, Hussy N, Evans RJ, Adami N, North RA, Surprenant A, and Buell G (1994) A new class of ligand-gated ion channel defined by P2x receptor for extracellular ATP. Nature 371:516-519.
108. Virginio C, Robertson G, Surprenant A, and North RA (1998) Trinitrophenylsubstituted nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2/3 receptors. Mol Pharmacol 53:969-973.
109. Webb TE, Simon J, Krishek BJ, Bateson AN, Smart TG, King BF, Burnstock G, and Barnard EA (1993) Cloning and functional expression of a brain G-protein-coupled ATP receptor. FEBS Lett 324:219-225.
110. Werner P, Seward EP, Buell GN, and North RA (1996) Domains of P2X receptors involved in desensitization. Proc Natl Acad Sci USA 93:15485-15490.
111. Wickenden A, Priest B, and Erdemli G (2012) Ion channel drug discovery: challenges and future directions. Future Med Chem 4:661-679.
112. Wilson HL, Wilson SA, Surprenant A, and North RA (2002) Epithelial membrane proteins induce membrane blebbing and interact with the P2X7 receptor C terminus. J Biol Chem 277:34017-34023.
113. Wolf C, Rosefort C, Fallah G, Kassack MU, Hamacher A, Bodnar M, Wang H, Illes P, Kless A, and Bahrenberg G et al. (2011) Molecular determinants of potent P2X2 antagonism identified by functional analysis, mutagenesis, and homology docking. Mol Pharmacol 79:649-661.
114. Woolf CJ (2011) Central sensitization: implications for the diagnosis and treatment of pain. Pain 152(3, Suppl)S2-S15.
115. Ziyal R, Ziganshin AU, Nickel P, Ardanuy U, Mutschler E, Lambrecht G, and Burnstock G (1997) Vasoconstrictor responses via P2X-receptors are selectively antagonized by NF023 in rabbit isolated aorta and saphenous artery. Br J Pharmacol 120:954-960.